CY1107760T1 - Κυτταρα φακοϊικου εγκλεισμου - Google Patents

Κυτταρα φακοϊικου εγκλεισμου

Info

Publication number
CY1107760T1
CY1107760T1 CY20071101310T CY071101310T CY1107760T1 CY 1107760 T1 CY1107760 T1 CY 1107760T1 CY 20071101310 T CY20071101310 T CY 20071101310T CY 071101310 T CY071101310 T CY 071101310T CY 1107760 T1 CY1107760 T1 CY 1107760T1
Authority
CY
Cyprus
Prior art keywords
gag
cell lines
pol
proteins
inclusion
Prior art date
Application number
CY20071101310T
Other languages
English (en)
Inventor
Philippe Leboulch
Karen Westerman
Original Assignee
Genetix Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetix Pharmaceuticals Inc. filed Critical Genetix Pharmaceuticals Inc.
Publication of CY1107760T1 publication Critical patent/CY1107760T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Abstract

Αποκαλύπτονται νέες κυτταρικές γραμμές εγκλεισμού οι οποίες παράγουν ανασυνδυαστικό ρετροϊό, χωρίς ανιχνεύσιμο ιό βοηθό. Επίσης αποκαλύπτονται μέθοδοι κατασκευής των κυτταρικών γραμμών και μέθοδοι παραγωγής ανασυνδυαστικών ρετροϊών από τις κυτταρικές γραμμές. Οι ρετροϊοί που παράγονται από τις κυτταρικές γραμμές περικλείουν φακοϊούς, όπως HIV, ικανούς μεταφοράς ετερόλογου DNA σε ένα ευρύ φάσμα μη-διαιρούμενων κυττάρων. Τα κύτταρα εγκλεισμού περιέχουν τουλάχιστον τρεις φορείς που κωδικοποιούν συλλογικά ρετροϊικές πρωτεΐνες gag, pol, και env, όπου τα γονίδια gag και pol είναι διαχωρισμένα, εν μέρει, επάνω σε δύο ή περισσότερους διαφορετικούς φορείς. Αυτό πραγματοποιείται με σύντηξη Vpr ή Vpx σε πρωτεΐνες pol που διαχωρίζονται από το gag έτσι ώστε οι πρωτεΐνες να στοχοθετούνται σε συγκροτούμενα ιϊκά σωματίδια. Μεταξύ άλλων πλεονεκτημάτων, τα κύτταρα εγκλεισμού παρέχουν το όφελος της αυξημένης ασφάλειας όταν χρησιμοποιούνται σε ανθρώπινη γονιδιακή θεραπεία ουσιαστικά απαλείφοντας την πιθανότητα μοριακού ανασυνδυασμού που οδηγεί στην παραγωγή ικανού αναπαραγωγής ιού βοηθού.
CY20071101310T 1998-05-13 2007-10-11 Κυτταρα φακοϊικου εγκλεισμου CY1107760T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8528398P 1998-05-13 1998-05-13
EP99923020A EP1076715B1 (en) 1998-05-13 1999-05-13 Lentiviral packaging cells

Publications (1)

Publication Number Publication Date
CY1107760T1 true CY1107760T1 (el) 2013-06-19

Family

ID=22190591

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101310T CY1107760T1 (el) 1998-05-13 2007-10-11 Κυτταρα φακοϊικου εγκλεισμου

Country Status (11)

Country Link
US (4) US6365150B1 (el)
EP (1) EP1076715B1 (el)
AT (1) ATE367447T1 (el)
AU (1) AU3988799A (el)
CA (1) CA2328404C (el)
CY (1) CY1107760T1 (el)
DE (1) DE69936577T2 (el)
DK (1) DK1076715T3 (el)
ES (1) ES2291025T3 (el)
PT (1) PT1076715E (el)
WO (1) WO1999058701A1 (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020173643A1 (en) * 1995-04-14 2002-11-21 Kappes John C. Fusion protein delivery system and uses thereof
US5994136A (en) * 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999058701A1 (en) * 1998-05-13 1999-11-18 Genetix Pharmaceuticals, Inc. Novel lentiviral packaging cells
US6555342B1 (en) 1998-06-03 2003-04-29 Uab Research Foundation Fusion protein delivery system and uses thereof
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
WO2000066759A1 (en) * 1999-04-29 2000-11-09 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1103615A1 (en) * 1999-11-25 2001-05-30 Universite De Geneve Vectors capable of immortalizing non-dividing cells and cells immortalized with said vectors
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
WO2002083080A2 (en) * 2001-04-17 2002-10-24 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
WO2002087341A1 (en) * 2001-05-01 2002-11-07 Genetix Pharmaceuticals, Inc. Novel self-inactivating (sin) lentiviral vectors
US8216585B2 (en) 2001-05-25 2012-07-10 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
BR0214275A (pt) 2001-11-19 2004-09-21 Scil Technology Gmbh Dispositivo tendo propriedades osteocondutora e osteoindutora
ES2260685T3 (es) * 2002-09-10 2006-11-01 Scil Technology Gmbh Implante metalico recubierto, a una concentracion de oxigeno reducida, con proteina osteoinductora.
KR100553154B1 (ko) * 2002-10-21 2006-02-22 유지창 Ｈｉｖ 뉴클레오캡시드 단백질의 동물세포 발현용 벡터 및 이의 제조방법
US8163542B2 (en) * 2003-05-19 2012-04-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Potent combinations of mRNA transport elements
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
EP2425001A4 (en) 2009-04-30 2012-11-14 Univ California ANTI-HIV COMBINATION VECTORS, TARGETING VECTORS AND METHOD OF USE
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
JP6514717B2 (ja) 2014-04-25 2019-05-15 ザ チルドレンズ メディカル センター コーポレーション 異常ヘモグロビン症を治療するための組成物および方法
EA201891717A1 (ru) 2016-02-23 2019-02-28 Иммьюн Дизайн Корп. Препараты мультигеномных ретровирусных векторов и способы и системы для их получения и применения
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
CA3109924A1 (en) 2018-08-24 2020-02-27 Csl Behring Gene Therapy, Inc. Vector production in serum free media
WO2020102709A1 (en) * 2018-11-16 2020-05-22 The Regents Of The University Of California Compositions and methods for delivering crispr/cas effector polypeptides
US11912986B2 (en) 2019-09-23 2024-02-27 The Regents Of The University Of California Methods for screening genetic perturbations
CN113186353A (zh) * 2021-05-28 2021-07-30 杭州晶佰生物技术有限公司 针对c型逆转录病毒的数字pcr检测用引物及检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861161A (en) 1994-09-07 1999-01-19 Universite De Montreal Chimeric proteins comprising a Vpr/Vpx virion incorporation domain for targeting into HIV-1 or HIV-2 virions
DE69637677D1 (de) 1995-04-14 2008-10-23 Univ Alabama Res Found Transfer system basierend auf einem fusionsprotein und seine anwendungen.
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997017457A2 (en) 1995-11-08 1997-05-15 Whitehead Institute For Biomedical Research Stable packaging cell line producing pseudotyped retroviruses
CA2265522A1 (en) * 1996-09-17 1998-03-26 The Salk Institute For Biological Studies Retroviral vectors capable of transducing non-dividing cells
US5908773A (en) 1996-09-20 1999-06-01 Cornell Research Foundation, Inc. KSHV positive cell lines
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
GB9621679D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Improved retroviral vectors
WO1999058701A1 (en) * 1998-05-13 1999-11-18 Genetix Pharmaceuticals, Inc. Novel lentiviral packaging cells

Also Published As

Publication number Publication date
CA2328404A1 (en) 1999-11-18
US8034620B2 (en) 2011-10-11
CA2328404C (en) 2007-07-24
ATE367447T1 (de) 2007-08-15
PT1076715E (pt) 2007-10-26
DE69936577D1 (de) 2007-08-30
ES2291025T3 (es) 2008-02-16
US20080187997A1 (en) 2008-08-07
AU3988799A (en) 1999-11-29
US20020168346A1 (en) 2002-11-14
US20050170507A1 (en) 2005-08-04
EP1076715A1 (en) 2001-02-21
US7311907B2 (en) 2007-12-25
DE69936577T2 (de) 2008-04-30
WO1999058701A1 (en) 1999-11-18
DK1076715T3 (da) 2007-11-19
US6365150B1 (en) 2002-04-02
EP1076715B1 (en) 2007-07-18
US6955919B2 (en) 2005-10-18

Similar Documents

Publication Publication Date Title
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
ES2153654T3 (es) Vectores retrovirales.
Mochizuki et al. High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells
ATE485367T1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
HUP0000442A2 (hu) Lentivirális vektorok
ATE381624T1 (de) Retrovirale vektoren mit verminderter rekombinationsrate
DE59911900D1 (de) Retrovirale, mit LCMV-Glykoprotein pseudotypisierte Hybrid-Vektoren
Coffin Genetic variation in retroviruses
EP0816487A4 (en) CELL THAT PRODUCES RECOMBINANT HIV
DE69534948D1 (de) Retrovirale vektoren zur expression in embryonalen zellen
NO983375D0 (no) Retroviral vektor og anvendelse derav i genterapi
PT975783E (pt) "vectores retrovirais, processo para a sua producao e sua utilizacao para a transferencia de genes a celulas cd4-positivas"
FI903976A0 (fi) Gener och av dessa kodade proteiner som regulerar genexpression av interleukin-2-receptor och humana lymfotropiska retrovirus.
Lin et al. Feline immunodeficiency virus vectors for efficient transduction of primary human synoviocytes: application to an original model of rheumatoid arthritis
ES2229674T3 (es) Verctor retroviral reconstituyente (vector re con) para la expresion de genes dirigidos.
ATE438714T1 (de) Molekulare klone mit mutierten hiv gag/pol, siv gag und siv env gene
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
Srinivasakumar et al. Novel Tat-encoding bicistronic human immunodeficiency virus type 1-based gene transfer vectors for high-level transgene expression
ES2053014T5 (es) El retrovirus sivcpz-ant y sus usos.
ATE417108T1 (de) Hiv-2 und siv-1 nukleotidsequenzen
Trono et al. Lentiviral Vectors for Gene Delivery in the Nervous System